RxDoctor Payments Data

Shashi Husain, MD

Neurology · Tulsa, OKNPI 1750324844

Payments from drug & device makers

$1,729in general payments, 2019–2025

Across 95 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$331
  • AbbVie$204
  • Novartis$148
  • Biogen$109
  • UCB, Inc.$77
  • Supernus Pharmaceuticals, Inc.$72
  • plus $788 from 24 others

What the payments were for

  • Food & beverage$1,69998%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,729 in reported general payments places this provider in the 50th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$306,435
Medicare patients
235
Services billed
20,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant108$132,490
IngrezzaValbenazine Tosylate15$112,412
XcopriCenobamate38$59,005
BriviactBrivaracetam23$37,325
BotoxOnabotulinumtoxina25$32,710
FycompaPerampanel24$26,576
Emgality PenGalcanezumab-Gnlm14$14,990
NamzaricMemantine Hcl/Donepezil Hcl21$11,937
NeuproRotigotine13$11,035
Gabapentin297$3,878
Lamotrigine270$3,107
Levetiracetam114$2,389
Baclofen162$2,303
Primidone148$2,155
Carbamazepine ErCarbamazepine27$2,094

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Botox, Namzaric$204$177,136154 claims
SK Life Science, Inc.Xcopri$331$59,00538 claims
UCB, Inc.Briviact, Neupro$77$48,36036 claims
Eisai Inc.Fycompa$62$26,57624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 152 neurology providers in Oklahoma.

Other neurology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →